

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>UNITED THERAPEUTICS Corp</u>  (Last) (First) (Middle) <u>1040 SPRING STREET</u>  (Street) <u>SILVER SPRING MD 20910</u>  (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>05/01/2019</u>	3. Issuer Name and Ticker or Trading Symbol <u>TransMedics Group, Inc. [ TMDX ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director <input checked="" type="checkbox"/> 10% Owner  Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series E Convertible Preferred Stock	(1)	(1)	Common Stock	1,874,923 <sup>(1)</sup>	(1)	I	By Lung Biotechnology PBC <sup>(2)</sup>
Series F Convertible Preferred Stock	(1)	(1)	Common Stock	678,317 <sup>(1)</sup>	(1)	I	By Lung Biotechnology PBC <sup>(2)</sup>

1. Name and Address of Reporting Person* <u>UNITED THERAPEUTICS Corp</u>  (Last) (First) (Middle) <u>1040 SPRING STREET</u>  (Street) <u>SILVER SPRING MD 20910</u>  (City) (State) (Zip)		
--	--	--

1. Name and Address of Reporting Person* <u>Lung Biotechnology PBC</u>  (Last) (First) (Middle) <u>1040 SPRING STREET</u>  (Street) <u>SILVER SPRING MD 20910</u>  (City) (State) (Zip)		
--	--	--

**Explanation of Responses:**

1. As of the date of this Form 3, the Preferred Stock reported herein is preferred stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization, by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated as of April 15, 2019, such preferred stock of TransMedics, Inc. will be converted into shares of common stock of the Issuer based on (i) the one-for-one ratio on which such shares of preferred stock of TransMedics Inc. are convertible into shares of common stock of TransMedics Inc. according to their terms and (ii) the 3.5-for-one ratio on which shares of common stock of TransMedics, Inc. will be converted into shares of common stock of the Issuer (the "Conversion"). The Preferred Stock has no expiration date. The number of shares in Column 3 reflects the Reporting Person's holdings following the Conversion.

2. The securities reported as being indirectly beneficially owned by United Therapeutics Corporation are directly beneficially owned by Lung Biotechnology PBC. Lung Biotechnology PBC is a wholly-owned subsidiary of United Therapeutics Corporation.

By: /s/ John S. Hess, Jr.,  
Executive Vice President,

05/01/2019

[Deputy General Counsel and  
Assistant Secretary, United  
Therapeutics Corporation](#)

[By: /s/ John S. Hess, Jr.,  
Executive Vice President,](#)

[Deputy General Counsel and  
Assistant Secretary, Lung  
Biotechnology PBC](#)      [05/01/2019](#)

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**